Risk Stratification and Role of Implantable Defibrillators for Prevention of Sudden Death in Patients With Hypertrophic Cardiomyopathy
Key result
Implantable cardioverter-defibrillators effectively prevent sudden cardiac death in hypertrophic cardiomyopathy patients, with appropriate intervention rates of 11% for secondary and 4% for primary prevention.
Why the study?
Do implantable cardioverter-defibrillators prevent sudden cardiac death in patients with hypertrophic cardiomyopathy?
Population
Patients with hypertrophic cardiomyopathy (HCM)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports ICD use in high-risk HCM; leaves open need for randomized data on primary prevention selection.
Structured PICO
Do implantable cardioverter-defibrillators prevent sudden cardiac death in patients with hypertrophic cardiomyopathy?
P
Population
Patients with hypertrophic cardiomyopathy (HCM)
I
Intervention
Implantable cardioverter-defibrillators (ICDs)
O
Outcome
Prevention of sudden cardiac death (SCD)hard clinical
ICDs are an effective strategy for preventing sudden cardiac death and prolonging life in patients with hypertrophic cardiomyopathy, guided by established risk factor algorithms.
Limitations
- Targeting candidates for prophylactic ICD therapy is complex due to unpredictable arrhythmogenic substrate, absence of a dominant risk factor, and difficulty in assembling randomized trials.
Cite This Study
Barry J. Maron (2010) conducted a review in Hypertrophic cardiomyopathy (HCM). Implantable cardioverter-defibrillators (ICDs) was evaluated on Appropriate intervention rates for prevention of sudden cardiac death. Implantable cardioverter-defibrillators effectively prevent sudden cardiac death in hypertrophic cardiomyopathy patients, with appropriate intervention rates of 11% for secondary and 4% for primary prevention.